- GHK-Cu has human skin trials, almost all topical: a positive trial of a gel in diabetic foot ulcers, and one well-designed independent facial trial that found no objective benefit.
- Matrixyl (palmitoyl pentapeptide-4) is a cosmetic ingredient whose human studies are small and largely industry-run.
- Oral hydrolysed collagen is a food supplement with the largest body of randomized skin trials of anything here.
- BPC-157's skin and wound findings are preclinical. Epithalon has no skin-specific human trial.
- COL1A1, SOD2, TGFB1 and MMP1 variants are linked to collagen and skin biology. None has been tested as a predictor of response to any skin peptide.
"Peptides for skin" covers two different things. Cosmetic peptides such as Matrixyl are ingredients in creams. Other compounds, such as GHK-Cu and BPC-157, have also been studied outside cosmetic use, and BPC-157 is not an approved medicine anywhere. The evidence behind each varies a great deal. This page sets out what each has been tested for and what was found. It does not rank them for anyone's skin.
A cream ingredient and an unapproved research compound are regulated and studied in completely different ways. Most of the human skin evidence on this page is for products applied to the skin.
1. GHK-Cu: the most-studied, with mixed human results
GHK-Cu is a copper-binding tripeptide found naturally in human blood. In lab work it delivers copper to lysyl oxidase, the enzyme that cross-links collagen and elastin, and it changes the expression of many genes; the widely quoted gene-expression figures come from cancer cell lines rather than skin.
Its human evidence is mostly topical. The strongest positive result is a randomized, placebo-controlled trial of a topical gel in diabetic foot ulcers, which reported better closure and fewer infections. For cosmetic skin, one well-designed independent facial trial found no objective benefit. No published human trial has tested GHK-Cu other than on the skin. Researchers have measured topical GHK-Cu crossing human skin, concentrated in the outer layers. Much of the foundational literature comes from one researcher who founded companies selling GHK-Cu products. The GHK-Cu reference page lists the trials.
2. Matrixyl: a cosmetic ingredient with small, industry-run studies
Matrixyl (palmitoyl pentapeptide-4) is a signal peptide used in over-the-counter creams. In lab studies it stimulates collagen production by skin cells. Its human studies are small and largely run or funded by ingredient and cosmetics companies, which reported reduced wrinkle measures. It is regulated as a cosmetic ingredient, not as a drug.
3. Oral hydrolysed collagen: a supplement, not a peptide drug
Hydrolysed collagen is a food supplement made from broken-down collagen. It has the largest set of randomized skin trials of anything on this page, and meta-analyses of those trials have reported improvements in skin hydration and elasticity. Collagen applied as a cream is a different matter: intact collagen molecules are too large to pass through the outer skin layer, so a collagen cream acts as a moisturiser.
4. BPC-157: preclinical wound data, no human skin trial
BPC-157's skin findings come from preclinical wound and burn models, where it was reported to speed healing. There is no published human trial of BPC-157 for skin, scars or wounds. It is not an approved medicine anywhere and is prohibited in sport at all times.
5. Epithalon: telomere research, no skin trial
Epithalon is a four-amino-acid peptide from Khavinson's Russian research program, studied for telomerase activation. Lab work has reported effects on telomere length and on the division capacity of cultured cells. There is no published human trial of Epithalon for skin. Most of its literature comes from a single research group. See Epithalon and telomere length for what that research shows.
How the evidence compares
| Compound | What it is | Human skin evidence | Regulatory status |
|---|---|---|---|
| GHK-Cu | Copper-binding tripeptide | Topical: positive in diabetic foot ulcers; no objective benefit in an independent facial trial | Cosmetic ingredient; no approved drug |
| Matrixyl | Cosmetic signal peptide | Small, largely industry-run studies | Cosmetic ingredient |
| Oral hydrolysed collagen | Food supplement | Many randomized trials; meta-analyses report hydration and elasticity changes | Dietary supplement |
| BPC-157 | 15-amino-acid gastric peptide | None; preclinical wound models only | Not approved anywhere |
| Epithalon | Tetrapeptide studied for telomerase | None skin-specific | Not approved in the US or EU |
For comparison, topical retinoids have a long record of randomized trials for photoageing, and tretinoin is an FDA-approved prescription drug for that use. GHK-Cu vs retinol and vitamin C sets the two side by side.
What genetics research does and does not show
Several genes are linked to skin structure and skin ageing. COL1A1 (rs1800012) has been linked to type I collagen production. SOD2 (rs4880) affects a mitochondrial antioxidant enzyme. MMP1 promoter variants affect an enzyme that breaks down collagen, and TGFB1 (rs1800469) has been studied in relation to scarring.
Those are associations with skin biology. None of them has been tested as a predictor of how anyone responds to GHK-Cu, Matrixyl, collagen, BPC-157 or Epithalon. No study has tested whether these genotypes change response to these compounds. A DNA report can show which versions you carry and what they have been linked to; it cannot tell you how your skin would respond to any of them.
The skin evidence is mostly for things applied to the skin or swallowed as food.
GHK-Cu has mixed topical trial results, Matrixyl has small industry studies, and oral collagen has the most randomized trials. BPC-157 and Epithalon have no human skin trial. No study has tested whether genetics predicts how a given person responds to any of them. A dermatologist is the right person for skin conditions and scarring.
Frequently asked questions
Which peptides have been studied for skin?
GHK-Cu has topical human trials, including a positive diabetic foot ulcer trial and an independent facial trial that found no objective benefit. Matrixyl has small, largely industry-run studies. Oral hydrolysed collagen has many randomized trials. BPC-157 and Epithalon have no human skin trial.
What has research found for GHK-Cu and wrinkles?
The evidence is mixed. GHK-Cu acts on collagen cross-linking and gene expression in lab studies, but the one well-designed independent trial on facial skin found no objective benefit. Its strongest positive human result is a topical gel in diabetic foot ulcers, a different problem from cosmetic ageing.
How does the research on GHK-Cu compare with Matrixyl?
Both are used in topical skin products. GHK-Cu has more published research, including independent trials, and its results for facial skin are mixed. Matrixyl's human studies are small and largely run by ingredient and cosmetics companies. Neither is an approved drug.
What have trials found for oral collagen and skin?
Oral hydrolysed collagen has the largest set of randomized skin trials of the compounds discussed here, and meta-analyses have reported improvements in skin hydration and elasticity. Collagen creams are different: intact collagen is too large to pass through the outer skin layer.
Has BPC-157 been tested on human skin or scars?
No. BPC-157's skin and wound findings come from preclinical models. There is no published human trial for skin, scars or wounds, and it is not an approved medicine anywhere.
Do genetics predict response to any skin peptide?
No study has shown that. COL1A1, SOD2, MMP1 and TGFB1 variants are linked to collagen, antioxidant and scarring biology, but none has been tested as a predictor of response to any skin peptide.
This article is for informational and educational purposes only. It reports what published research found; it is not medical advice, it does not diagnose, treat, cure or prevent any disease, and nothing in it is a dose or a recommendation to use any compound. Talk to a licensed clinician about any medical decision.